Boehringer Ingelheim Pharmaceuticals Paid $650M to Pradaxa Victims

January 23, 2017 | Ed Bernstein
Boehringer Ingelheim Pharmaceuticals Paid $650M to Pradaxa Victims

The U.S. Food & Drug Administration approved the use of anticoagulant Pradaxa (Dabigatran) in October 2010. By 2011, more than 500 patients who were using the drug had died, and thousands more had suffered injuries, according to USA Today. \ In 2014, Pradaxa manufacturer Boehringer Ingelheim Pharmaceuticals agreed to pay $650 million to settle nearly 4,000 federal and state lawsuits. That particular case may have ended two years ago, but Pradaxa victims can still file lawsuits against Boehringer Ingelheim. In fact, at least four class-action lawsuits have been filed in 2016. If you suffered uncontrolled bleeding in your brain, rectum or intestines while taking Pradaxa, or if your loved one died while using the drug, contact Ed Bernstein & Associates. Our legal team will evaluate your case to determine if you have grounds for a lawsuit. Call 702-240-0000 today to schedule a free consultation with a personal injury lawyer in Las Vegas. Plaintiffs Claim Boehringer Ingelheim Pharmaceuticals Concealed the Dangers of Pradaxa The victims of Pradaxa have made several claims against the drug’s manufacturer. Some have argued that the company concealed the dangers that the drug poses to patients. Other plaintiffs argued that Boehringer Ingelheim marketed the drug as safer than Warafin yet the research indicated that Pradaxa was just as likely – or even more likely – to cause bleeding events. The lawsuits also claim that the original label of the drug was inaccurate and lacked important details. For example, the drug’s label did not:

  • Warn patients about the potential for gastrointestinal bleeding;
  • Explain the dosage requirements according to the patient’s weight;
  • Warn patients about the risk of bleeding in elder patients; or
  • Warn patients that if a bleeding event occurs, there was no treatment available.
According to Modern Medicine, the FDA recently approved Praxbind, an agent that has proven effective for reversing the effects of Pradaxa in patients who are suffering uncontrolled or life-threatening bleeding. In a study involving 123 patients who were taking Dabigatran and required anticoagulation reversal or emergency surgery, Praxbind fully reversed the effects of Dabigatran in 89 percent of the participants within the first four hours of receiving the reversal agent. Sadly, 26 patients in the study died. Although Praxbind offers hope for patients who have suffered the ill effects of Pradaxa, this cure has come too late for thousands of victims. If you or your loved one suffered uncontrollable bleeding due to Pradaxa, contact Ed Bernstein & Associates. Our firm has been representing the injured for more than 40 years, and we have the knowledge and resources to represent your interests. You may be entitled to compensation for medical bills and lost income that resulted from the adverse effects of Pradaxa. If you lost a family member due to Pradaxa, our legal team will help you file a wrongful death lawsuit. Our office is available 24 hours a day, seven days a week. Call 702-240-0000 to schedule a free consultation with an injury attorney in Las Vegas.


Ed Bernstein

Edward M. Bernstein, Esq. is the owner and founding partner of Edward M. Bernstein & Associates, and one of the most recognizable figures in Nevada. Ed is one of state’s premier personal injury attorneys and has hosted The Ed Bernstein Show for over 31 years. He has served the Las Vegas community for decades with dozens of community appointments and terms of service. In the year 2000, he was Nevada’s Democratic nominee for the United States Senate.

Ed received his B.A. from Long Island University in 1971 and his J.D. from Widener University in 1975. Since then, Ed’s professional accolades include numerous publications, honors and awards, court appointments, and has been named one of America’s Top 100 High Stakes Litigators.